Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Mortality and Morbidity in Adults With Rheumatic Heart Disease.
JAMA
July 2024
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Importance: Rheumatic heart disease (RHD) remains a public health issue in low- and middle-income countries (LMICs). However, there are few large studies enrolling individuals from multiple endemic countries.
Objective: To assess the risk and predictors of major patient-important clinical outcomes in patients with clinical RHD.
Incorporating high-resolution climate, remote sensing and topographic data to map annual forest growth in central and eastern Europe.
Sci Total Environ
February 2024
TUM School of Life Sciences, Technical University of Munich, Germany.
Article Synopsis
- - The study emphasizes the importance of high-resolution annual forest growth maps, using tree-ring width (TRW) data, to better understand forest carbon sequestration and the impact of climate change and drought on forest ecosystems.
- - By integrating high-resolution Earth observation data with climate and topography information, the researchers found that species-specific models could explain over 52% of variance in tree growth, enhancing the accuracy of growth predictions compared to using just climate and elevation data.
- - The research successfully generated a map of annual TRW for 2021, demonstrating that combining different data sources can lead to more effective models for forest growth, while also identifying areas where predictions may be less reliable, particularly in climate marginal zones.
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
N Engl J Med
September 2022
From the Population Health Research Institute, McMaster University, Hamilton, ON, Canada (S.J.C., A.B., A.K., D.P., K.B., S.R., C.R., S.Y.); the All India Institute of Medical Sciences, New Delhi (G.K.); the Division of Cardiology, Faculty of Health Sciences, University of Cape Town (M.N., B.M.), and the South African Medical Research Council (L.Z.) - both in Cape Town, South Africa; Jimma University Medical Center, Jimma, Ethiopia (A.H.); the University of Gazira, Wad Madani, Sudan (A.E.S.); Mahalla Heart Center, El Mahalla El Kubra (A.E.G.), and Suez Canal University Hospital, Ismailia (F.M.) - both in Egypt; the Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique (A.D.); the International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo (A.A.); the College of Medicine, University of the Philippines, Manila (A.M.L.D.); Kenyatta National Hospital, Nairobi (B.G.); the People's Hospital of Peking University (D.H.) and the Beijing Anzhen Hospital (C.M.) - both in Beijing; the University Teaching Hospital of Kigali, Kigali, Rwanda (E.R.K.); the University of Zimbabwe, College of Health Sciences, Harare (G.F.); Instituto Nacional de Cardiología Ignacio Chávez, Mexico City (J.A.G.-H.); the University Teaching Hospital, Lusaka, Zambia (J.M.); the National Institute of Cardiovascular Diseases, Karachi, Pakistan (K.K.); Kamuzu Central Hospital, Lilongwe, Malawi (L.G.); Barrio Obrero Hospital, Asuncion, Paraguay (M.P.); the Department of Medicine, University of Ibadan-College Hospital, Ibadan, Nigeria (O.S.O.); Princess Marina Hospital, University of Botswana, Gaborone (O.J.M.-B.); Uganda Heart Institute, Kampala (P.L.); Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania (P.C.); the B.P. Koirala Institute of Health Sciences, Dharan, Nepal (S.K.S.); St. Elizabeth Catholic General Hospital, Kumbo, Cameroon (T.T.J.C.); the Department of Medicine, University of Saskatchewan, Saskatoon, the Department of Medicine, Western University, London, ON, and the Windsor Cardiac Centre, Windsor, ON - all in Canada (W.M.T.); the Department of Cardiology, Cardiology I, University Medical Center Mainz, Johannes Gutenberg University, Mainz (A.B.), and Bayer, Berlin (M.E.) - both in Germany.
Background: Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited.
Methods: We enrolled patients with atrial fibrillation and echocardiographically documented rheumatic heart disease who had any of the following: a CHADSVASc score of at least 2 (on a scale from 0 to 9, with higher scores indicating a higher risk of stroke), a mitral-valve area of no more than 2 cm, left atrial spontaneous echo contrast, or left atrial thrombus. Patients were randomly assigned to receive standard doses of rivaroxaban or dose-adjusted vitamin K antagonist.
[Personalities in the history of medicine. Johannes Evangelista Purkinje].
Praxis (Bern 1994)
December 2014
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!